Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Urologie in der Praxis 1/2018

31.01.2018 | Extended Abstract

Testosteron – Benzin für den Mann?

verfasst von: Dr. med. Marco Randazzo

Erschienen in: Urologie in der Praxis | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten
share
TEILEN

Auszug

Gibt es die Andropause beim Mann? Sicher ist, dass der Testosteronwert kontinuierlich ab einem gewissen Alter abfällt: Ab dem 40. Lebensjahr beträgt diese Reduktion rund 1 %; umgekehrt steigt das sexualhormonbindende Globulin (SHBG) langsam an. Ein Charakteristikum des älter werdenden Mannes ist die langsame Sarkopenie verbunden mit einem langsam steigenden Körperfettanteil. …
Literatur
1.
Zurück zum Zitat Kallman DA, Plato CC, Tobin JD (1990) The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives. J Gerontol 45:M82–88 CrossRefPubMed Kallman DA, Plato CC, Tobin JD (1990) The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives. J Gerontol 45:M82–88 CrossRefPubMed
2.
Zurück zum Zitat Orwoll ES, Oviatt SK, McClung MR, Deftos LJ, Sexton G (1990) The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med 112:29–34 CrossRefPubMed Orwoll ES, Oviatt SK, McClung MR, Deftos LJ, Sexton G (1990) The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med 112:29–34 CrossRefPubMed
3.
Zurück zum Zitat Fleg JL, Lakatta EG (1988) Role of muscle loss in the age-associated reduction in VO2 max. J Appl Physiol 65(3):1147–1151 CrossRefPubMed Fleg JL, Lakatta EG (1988) Role of muscle loss in the age-associated reduction in VO2 max. J Appl Physiol 65(3):1147–1151 CrossRefPubMed
4.
Zurück zum Zitat Horber FF, Gruber B, Thomi F, Jensen EX, Jaeger P (1997) Effect of sex and age on bone mass, body composition and fuel metabolism in humans. Nutrition 13:524–534 CrossRefPubMed Horber FF, Gruber B, Thomi F, Jensen EX, Jaeger P (1997) Effect of sex and age on bone mass, body composition and fuel metabolism in humans. Nutrition 13:524–534 CrossRefPubMed
5.
Zurück zum Zitat Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore Longitudinal Study of Aging (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724–731 CrossRefPubMed Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore Longitudinal Study of Aging (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724–731 CrossRefPubMed
6.
Zurück zum Zitat Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ (1997) Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46:410–413 CrossRefPubMed Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ (1997) Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46:410–413 CrossRefPubMed
7.
Zurück zum Zitat Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, European Aging Study MG (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93:2737–2745 CrossRefPubMed Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, European Aging Study MG (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93:2737–2745 CrossRefPubMed
8.
Zurück zum Zitat Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT, Group E (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363:123–135 CrossRefPubMed Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT, Group E (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363:123–135 CrossRefPubMed
9.
Zurück zum Zitat Chute CG, Baron JA, Plymate SR, Kiel DP, Pavia AT, Lozner EC, O’Keefe T, MacDonald GJ (1987) Sex hormones and coronary artery disease. Am J Med 83:853–859 CrossRefPubMed Chute CG, Baron JA, Plymate SR, Kiel DP, Pavia AT, Lozner EC, O’Keefe T, MacDonald GJ (1987) Sex hormones and coronary artery disease. Am J Med 83:853–859 CrossRefPubMed
10.
Zurück zum Zitat Laughlin GA, Barrett-Connor E, Bergstrom J (2008) Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93:68–75 CrossRefPubMed Laughlin GA, Barrett-Connor E, Bergstrom J (2008) Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93:68–75 CrossRefPubMed
11.
Zurück zum Zitat Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Mellstrom D, Ohlsson C (2009) Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 94:2482–2488 CrossRefPubMed Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Mellstrom D, Ohlsson C (2009) Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 94:2482–2488 CrossRefPubMed
12.
Zurück zum Zitat Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH (2013) Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 169:725–733 CrossRefPubMed Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH (2013) Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 169:725–733 CrossRefPubMed
13.
Zurück zum Zitat Dong JY, Zhang YH, Qin LQ (2011) Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 58:1378–1385 CrossRefPubMed Dong JY, Zhang YH, Qin LQ (2011) Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 58:1378–1385 CrossRefPubMed
14.
Zurück zum Zitat Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, Morgentaler A (2015) Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 18:5–15 CrossRefPubMedPubMedCentral Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, Morgentaler A (2015) Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 18:5–15 CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS, Investigators T (2011) Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 34:828–837 CrossRefPubMedPubMedCentral Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS, Investigators T (2011) Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 34:828–837 CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L (2011) Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 165:675–685 CrossRefPubMedPubMedCentral Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L (2011) Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 165:675–685 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Hackett G (2016) An update on the role of testosterone replacement therapy in the management of hypogonadism. Ther Adv Urol 8:147–160 CrossRefPubMed Hackett G (2016) An update on the role of testosterone replacement therapy in the management of hypogonadism. Ther Adv Urol 8:147–160 CrossRefPubMed
18.
Zurück zum Zitat Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010) Adverse events associated with testosterone administration. N Engl J Med 363:109–122 CrossRefPubMedPubMedCentral Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010) Adverse events associated with testosterone administration. N Engl J Med 363:109–122 CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, Wenger NK, Bhasin S, Barrett-Connor E, Swerdloff RS, Stephens-Shields A, Cauley JA, Crandall JP, Cunningham GR, Ensrud KE, Gill TM, Matsumoto AM, Molitch ME, Nakanishi R, Nezarat N, Matsumoto S, Hou X, Basaria S, Diem SJ, Wang C, Cifelli D, Snyder PJ (2017) Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA 317:708–716 CrossRefPubMedPubMedCentral Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, Wenger NK, Bhasin S, Barrett-Connor E, Swerdloff RS, Stephens-Shields A, Cauley JA, Crandall JP, Cunningham GR, Ensrud KE, Gill TM, Matsumoto AM, Molitch ME, Nakanishi R, Nezarat N, Matsumoto S, Hou X, Basaria S, Diem SJ, Wang C, Cifelli D, Snyder PJ (2017) Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA 317:708–716 CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER 3rd, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS, Testosterone Trials I. (2016) Effects of testosterone treatment in older men. N Engl J Med 374:611–624 CrossRefPubMedPubMedCentral Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER 3rd, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS, Testosterone Trials I. (2016) Effects of testosterone treatment in older men. N Engl J Med 374:611–624 CrossRefPubMedPubMedCentral
Metadaten
Titel
Testosteron – Benzin für den Mann?
verfasst von
Dr. med. Marco Randazzo
Publikationsdatum
31.01.2018
Verlag
Springer Vienna
Erschienen in
Urologie in der Praxis / Ausgabe 1/2018
Print ISSN: 2661-8737
Elektronische ISSN: 2661-8745
DOI
https://doi.org/10.1007/s41973-018-0021-z

Weitere Artikel der Ausgabe 1/2018

Urologie in der Praxis 1/2018 Zur Ausgabe

Extended Abstract

Autoerotische Unfälle

Extended Abstract

Sterilität der Frau